An observational study in Severe Eosinophilic Asthma, sponsored by AstraZeneca. Recruiting at 28 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by AstraZeneca · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission.
The ATHENA study aims to expand real-world evidence on benralizumab role in clinical practice, specifically evaluating its effectiveness in achieving clinical remission (complete and partial), as defined by SANI. Additionally, given the growing importance of biomarkers in asthma research, this study seeks to further investigate benralizumab immunological effects, potentially contributing to a deeper understanding of asthma pathophysiology and addressing existing knowledge conundrum. Additionally, the study will consolidate long-term safety data.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.
Counted across the registry records on this site, refreshed daily.
Severe eosiniphilic asthma patients treated with benralizumab as per clinical practices
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
30mg s.c. as per SmPC
Also known as: Fasenra
Number and percentage of patients achieving clinical remission, partial and complete, as per SANI Definition
Number and percentage of patient who met the 4 remission criteria (complete or partial) at 12 months and maintained up to 24months
Time frame: 24 months
Number and percentage of patients achieving the criteria for clinical remission
Number and percentage of patient with the criteria for complete or partial remission according to the following criteria: No need to use OCS; Absence of asthma symptoms (ACT score from 20/25 to 25/25); Absence of asthma exacerbations; Stable lung function (FEV1 decline of no more than 100 mL).
Time frame: 3, 6, 12 and 24 months
Rate of any and SA exacerbations
annualized exacerbations rate
Time frame: 3, 6, 12 and 24 months
Mean change in Asthma Control Test (ACT) score
mean (SD) changes (min - max) overtime in ACT score
Time frame: 1, 3, 6, 12 and 24 months vs baseline
Mean changes in Asthma Control Questionnaire (ACQ) score
mean (SD) changes (min - max) overtime in ACQ score
Time frame: 1, 3, 6, 12 and 24 months vs baseline
Mean change in FEV1 - pre-BD
mean (SD) changes in FEV1 (L) overtime
Time frame: 3, 6, 12 and 24 vs baseline
Mean changes in FEV1 - post-BD
mean (SD) changes in FEV1 (L) post-BD
Time frame: 3, 6, 12 and 24 months vs baseline
Mean changes in FEV1 % predicted - pre-BD
mean (SD) changes in FEV1 % predicted pre-BD
Time frame: 3, 6, 12 and 24 months vs baseline
Mean changes in FEV1 % predicted - post-BD
mean (SD) changes in FEV1 % predicted post-BD
Time frame: 3, 6, 12 and 24 months vs baseline
Mean changes in FVC pre-BD
mean (SD) changes in FVC (L) pre-BD
Time frame: 3, 6, 12 and 24 months vs baseline
Mean changes in FVC post-BD
mean (SD) changes in FVC (L) post-BD
Time frame: 3, 6, 12 and 24 months vs baseline
Mean changes in pre-BD FEV1/FVC
mean (SD) changes in pre-BD FEV1/FVC (ratio)
Time frame: 3, 6, 12 and 24 months vs baseline
Mean changes in pre-BD FEF 25-75
mean (SD) changes in pre\_BD FEF25-75 (L/sec)
Time frame: 3, 6, 12 and 24 months vs baseline
Mean changes in post-BD FEF 25-75
mean (SD) changes in post-BD FEF25-75 (L/sec)
Time frame: 3, 6, 12 and 24 months vs baseline
Mean changes in post-BD FEV1/FVC
mean (SD) changes in post-BD FEV1/FVC (ratio)
Time frame: 3, 6, 12 and 24 months vs baseline
Change in inhaled maintenance therapy and inhaled corticosteroid (ICS/LABA/LAMA, ICS/LABA) use and dosage
Change in inhaled maintenance therapy and inhaled corticosteroid (ICS/LABA/LAMA, ICS/LABA) use and dosage after benralizumab treatment
Time frame: 3, 6, 12 and 24 months
Change in mOCS use and daily dose
Change in mOCS use and daily dose after benralizumab administartion
Time frame: 3, 6, 12 and 24 months
Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Eosinophilia